Femasys(FEMY)
Focus: Femasys is a publicly-traded women's health-focused medical device and fertility company headquartered in Suwanee, GA, with a portfolio spanning contraception, fertility diagnostics, and assisted reproductive technologies. Founded in 2024, the company is early-stage with minimal revenue ($2M in FY2025) but significant R&D investment.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Femasys
AI assessmentNot HiringNo open roles listed right now. Follow Femasys to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Femasys's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$2M
FY2025
Pipeline & Clinical Trials
FemBloc
ContraceptionClinical Trials (1)
NCT03433911FemBloc® Permanent Contraception - Early Pivotal Trial
N/AHelp build intelligence for Femasys
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.